Synendos Therapeutics AG
Developing therapies for neuropsychiatric disorders.
Synendos is a clinical stage neuroscience company developing breakthrough safe and effective therapies for neuropsychiatric disorders such as PTSD, through modulation of a new drug target that enables restoration of the natural functioning of the brain. Our lead drug candidate, SYT-510, belongs to a novel class of ECS modulators named Selective Endocannabinoid Re-uptake Inhibitors (SERIs). Pre-clinical development of SYT-510 has been successfully completed, the CTA has been approved by the EMA and the first Phase 1 clinical trial has begun in early 2024. We plan to validate the potential of this novel mode of action through completion of early clinical development including a Proof-of-Concept study in patients.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
31.10.2025
More than 20 Swiss biotech companies to exhibit at Bio Europe (startupticker.ch)
02.10.2025
Life sciences companies make positive progress (startupticker.ch)
01.09.2025
New Startup Innovation Projects set to advance their technologies (startupticker.ch)
14.08.2025
Four startups welcome new leaders to accelerate growth (startupticker.ch)
18.03.2025
Swiss Economic Awards: Finalisten sind bekannt (startupticker.ch)
Last Tweets
No milestones
No Jobs
Videos
Testimonial FIlm sponsored by the Lichtsteiner Foundation
Pitching Synendos
SCSN 2019
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Venture Leaders Life Sciences
The venture leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.
Synendos Therapeutics AG
Developing therapies for neuropsychiatric disorders.
Website:
www.synendos.com
Headquarter:
Basel
Foundation Date:
April 2019
Technology:
- Biotech
Sectors:
- Biotech
- Drug discovery
- Neurology
- Small molecule drugs
Support received
